This is a correction of the announcement from 09:40 31.08.2016 CEST. Reason for the correction: To summarize key information from the interim report in the press release.
Hoersholm, Denmark; August 31st, 2016 - Medical Prognosis Institute A/S (MPI:ST) announces the Company's Interim Report First Half 2016. Below is a summary of the report.
Significant events during H1 2016
Significant events after the period
Financial review for H1 2016 (2016-01-01 to 2016-06-30)
The Report includes the Parent Company Medical Prognosis Institute A/S. No consolidated financial statements have been prepared with reference to section 110 of the Danish Financial Statements Act.
Income statement H1 2016
-203,4% (last year -932,4%). The increase in gross profit is due to increased sales of DRP licenses and analyses and that the vast majority of the direct costs are related to revenue generating activities.
No events materially affecting the assessment of the Report have occurred after the balance sheet date.
For the full Interim Report, please see www.medical-prognosis.com.
Certified Adviser: Sedermera Fondkommission
For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD
Telephone: +45 21 60 89 22
This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 31st august 2016.
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.